Kymera dou­bles down on pro­tein de­graders for im­munol­o­gy, chas­ing Dupix­ent and So­tyk­tu

Look­ing to fur­ther ex­pand the reach of pro­tein de­graders be­yond can­cer, Kymera Ther­a­peu­tics re­vealed two new pro­grams Thurs­day morn­ing that it hopes will com­pete with some of the hottest im­munol­o­gy drugs on the mar­ket.

One of Kymera’s com­pounds mim­ics Dupix­ent, an in­jec­tion that Re­gen­eron and Sanofi mar­ket for sev­er­al con­di­tions that is on track to gen­er­ate more than $10 bil­lion in an­nu­al sales. Kymera’s sec­ond new drug goes af­ter the same tar­get as So­tyk­tu, a pill sold by Bris­tol My­ers Squibb for plaque pso­ri­a­sis that’s be­ing test­ed for a bevy of im­mune-re­lat­ed con­di­tions.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER